Casey Eye Institute, Oregon Health & Science University, Portland, Oregon.
Byers Eye Institute, Stanford University, Palo Alto, California.
Ophthalmology. 2019 Jan;126(1):19-26. doi: 10.1016/j.ophtha.2018.05.019. Epub 2018 Jun 23.
To compare clinical outcomes of ultrathin Descemet stripping automated endothelial keratoplasty (UT-DSAEK) and Descemet membrane endothelial keratoplasty (DMEK) in the treatment of corneal endothelial dysfunction.
Patient and outcome-masked, randomized controlled clinical trial.
Patients with damaged or diseased endothelium from Fuchs endothelial dystrophy or pseudophakic bullous keratopathy who were considered good candidates for DMEK or UT-DSAEK.
Study eyes were randomized by the eye bank to UT-DSAEK or DMEK 1 to 2 days before surgery.
The primary outcome of the trial was best spectacle-corrected visual acuity (BSCVA) at 6 months. Secondary outcomes included 3- and 12-month BSCVA; 3-, 6-, and 12-month endothelial cell counts; intraoperative and postoperative complications; and change in pachymetry.
A total of 216 patients with endothelial dysfunction were screened, and 50 eyes of 38 patients were enrolled by 2 surgeons at Casey Eye Institute at Oregon Health & Science University in Portland, Oregon, and at Byers Eye Institute at Stanford University in Palo Alto, California. Overall, we found DMEK to have better visual acuity outcomes compared with UT-DSAEK after correcting for baseline visual acuity: compared with UT-DSAEK, those randomized to DMEK had 1.5 lines better BSCVA at 3 months (95% confidence interval [CI], 2.5-0.6 lines better; P = 0.002), 1.8 lines better BSCVA at 6 months (95% CI, 2.8-1.0 lines better; P < 0.001), and 1.4 lines better BSCVA at 12 months (95% CI, 2.2-0.7 lines better; P < 0.001). Average endothelial cell counts were 1963 cells/mm in DMEK and 2113 cells/mm in UT-DSAEK at 6 months (P = 0.17) and 1855 cells/mm in DMEK and 2070 cells/mm in UT-DSAEK at 12 months (P = 0.051). Intraoperative and postoperative complication rates were similar between groups.
Descemet membrane endothelial keratoplasty had superior visual acuity results compared with UT-DSAEK at 3, 6, and 12 months in patients with isolated endothelial dysfunction with similar complication rates.
比较超薄撕囊自动化角膜内皮移植术(UT-DSAEK)和去表皮内皮角膜移植术(DMEK)治疗角膜内皮功能障碍的临床疗效。
患者和结局设盲、随机对照临床试验。
患有 Fuchs 角膜内皮营养不良或白内障术后大泡性角膜病变导致的受损或患病内皮的患者,这些患者被认为是 DMEK 或 UT-DSAEK 的合适人选。
研究眼在手术前 1 至 2 天由眼库通过随机分配到 UT-DSAEK 或 DMEK。
试验的主要结局是 6 个月时最佳矫正视力(BSCVA)。次要结局包括 3 个月和 12 个月时的 BSCVA;3 个月、6 个月和 12 个月时的内皮细胞计数;术中及术后并发症;和角膜厚度的变化。
共有 216 名内皮功能障碍患者接受了筛查,俄勒冈健康与科学大学波特兰凯西眼科研究所和加利福尼亚斯坦福大学拜尔斯眼科研究所的 2 名外科医生共纳入了 38 名患者的 50 只眼。总的来说,我们发现经过基线视力校正后,DMEK 的视力结果优于 UT-DSAEK:与 UT-DSAEK 相比,随机接受 DMEK 的患者在 3 个月时的 BSCVA 提高了 1.5 行(95%置信区间[CI]:2.5-0.6 行;P=0.002),在 6 个月时提高了 1.8 行(95%CI:2.8-1.0 行;P<0.001),在 12 个月时提高了 1.4 行(95%CI:2.2-0.7 行;P<0.001)。6 个月时,DMEK 的平均内皮细胞计数为 1963 个/mm,UT-DSAEK 为 2113 个/mm(P=0.17),12 个月时,DMEK 的平均内皮细胞计数为 1855 个/mm,UT-DSAEK 为 2070 个/mm(P=0.051)。两组术中及术后并发症发生率相似。
在孤立性内皮功能障碍患者中,与 UT-DSAEK 相比,DMEK 在 3、6 和 12 个月时具有更好的视力结果,且并发症发生率相似。